ArticleNanoscale advances2020
Development of label-free gold nanoparticle based rapid colorimetric assay for clinical/point-of-care screening of cervical cancer.
Article in Nanoscale advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Bimetallic nano mixtures enable rapid ultrasensitive detection of high risk HPV for early cervical cancer diagnosis.Discover nano · 2026Article
- Scorpion Venom as a Source of Cancer Drugs: A Comprehensive Proteomic Analysis and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Understanding gold nanoparticles and their attributes in ovarian cancer therapy.Molecular cancer · 2025Review
- Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.Molecular cancer · 2025Article
- Gold nanoparticles in the diagnosis and treatment of ovarian and cervical cancers: a comprehensive understanding.Frontiers in oncology · 2025Review
- Multiplexed immunolabelling of cancer using bioconjugated plasmonic gold-silver alloy nanoparticles.Nanoscale advances · 2024Article
- Development of a Point-of-Care Cervico-Vaginal Sampling/Testing Device for the Colorimetric Detection of Cervical Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Point-of-care diagnosis of cervical cancer: potential protein biomarkers in cervicovaginal fluid.Turkish journal of biology = Turk biyoloji dergisi · 2022Review
- Small-volume detection: platform developments for clinically-relevant applications.Journal of nanobiotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the fourth largest cancer, affecting women across the globe. Rapid screening is of vital importance for diagnosis and treatment of the disease, especially in developing countries with high risk populations. In this paper, we report a simple, novel and rapid approach for qualitative screening of cervical cancer. A label-free colorimetric technique ("
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.